Positive clinical results of ACP-001 presented at EHA2022
XNK Therapeutics AB (“XNK”) today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial ACP-001 with its leading candidate drug was presented at European Hematology Association’s hybrid conference EHA2022, which is held in Vienna, Austria, on June 9[th]-12[th].